GLP-1 Transition Planner

Why most people regain after stopping

The STEP 1 trial extension¹Diabetes, Obesity and Metabolism · 2022Wilding JPH et al. — Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension documented that one year after stopping semaglutide, two-thirds of weight was regained and most cardiometabolic improvements reversed. The mechanism: the drug suppressed appetite pharmacologically. When the drug stops, appetite returns — often stronger because leptin levels are now lower and ghrelin higher (set-point defense). Without a structural lifestyle change taking the drug's place, regain is the rule, not the exception.

The muscle-mass problem

The Linge 2024 Obesity Reviews substudy²Obesity Reviews · 2024Linge J et al. — Body composition and cardiometabolic effects of GLP-1 receptor agonists: changes in lean mass documented that 25–40% of total weight lost on semaglutide is lean mass. The Jensen 2024 JAMA Network Open study³JAMA Network Open · 2024Jensen SBK et al. — Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment showed GLP-1 monotherapy reduced bone mineral density at hip and spine; concurrent exercise prevented this. So the question isn't whether to lose lean mass and bone — it's whether you take active countermeasures (resistance training + 1.8–2.0 g/kg protein) starting from day one. Most users don't. The protocol forces them to.

The 12-week off-ramp

The 12-week window is calibrated to the body-composition adaptation period — long enough to build strength training as a habit, recalibrate appetite, and adapt to the lower lean-mass state. Tapering doses (semaglutide: drop 1 level every 4 weeks; tirzepatide: drop 2.5–5 mg every 4 weeks) provides a gradual transition rather than a cliff. Always coordinate with your prescribing physician — this is not a substitute for clinical care, just a structured protocol to add alongside it.

If lifestyle alone proves insufficient

For some adults — particularly those with BMI starting above 40, severe metabolic syndrome, or cardiovascular disease — long-term GLP-1 use is the right call, same as long-term insulin or statin therapy is for analogous conditions. The SELECT trial⁴New England Journal of Medicine · 2023Lincoff AM et al. — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) demonstrated 20% reduction in cardiovascular events from semaglutide in obese non-diabetic adults. Stopping the drug is not a moral imperative. The transition planner helps for those whose cost-benefit calculus is favourable for stopping. For others, the right protocol is staying on the drug while adding the same protein and strength scaffolding.